StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.59 | $0.57 | -3.60% | 1.4M |
| 05-12 | $0.56 | $0.64 | +15.34% | 2.8M |
| 05-13 | $0.64 | $0.62 | -3.66% | 2.0M |
| 05-14 | $0.62 | $0.60 | -3.35% | 1.2M |
| 05-15 | $0.60 | $0.57 | -5.00% | 1.2M |
No sell-side coverage available for OSRH.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for OSRH.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 |
|---|---|---|---|---|
Revenue | $1.90M | $761.27K | $1.79M | $910.23K |
Operating Income | $-8.15M | $-2.92M | $-6.51M | $-3.30M |
Net Income | $-16.62M | $-11.39M | $-97.30K | $-60.43K |
EPS (Diluted) | $-0.69 | $-1.04 | $-1.00 | $-0.01 |
Total Assets | $185.42M | $174.55M | $20.63M | $37.27M |
Total Liabilities | $46.26M | $42.27M | $5.49M | $4.82M |
Cash & Equivalents | $1.58M | $1.60M | $119.12K | $3.64K |
Free Cash Flow OCF − CapEx | $-549.36K | Not available | Not available | Not available |
Shares Outstanding | 19.81M | 19.28M | 2.15M | 2.15M |
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.